<DOC>
	<DOCNO>NCT00334386</DOCNO>
	<brief_summary>Primary objective : To demonstrate no-inferiority efficacy treatment Torsemide-PR relation Torsemide-IR patient mild and/or moderate hypertension . Secondary objective : To evaluate safety tolerability Torsemide-PR .</brief_summary>
	<brief_title>Hypertension Study : Multinational Torasemide Trial Mild Moderate Hypertension .</brief_title>
	<detailed_description>Torsemide loop diuretic group pyridine-sulfonylureas , act ascend large portion Henle loop inhibits Na+/K+/2Cl- transport ! system block Cl- channels.Therefore , sodium chlorine ion water reabsorb tubule urine volume increase significantly . Torsemide use treatment oedema associate congestive heart failure , kidney liver disease , either alone combined anti-hypertensive drug , treatment arterial hypertension . This trial compare effect new formulation Torasemide ( Torasemide prolong release ) already available immediate release formulation drug treatment mild moderate hypertensive patient . Eligible patient randomise either treatment Torasemide prolong release Torasemide immediate release followed-up complete 3 month treatment.Blood pressure measure OMRON pressure gauge . Additionally , ABPM perform sub-group patient take part trial .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>1 . Aged 18 75 , inclusive . 2 . Ambulatory patient diagnose mild moderate arterial hypertension comply follow requirement : 1 . Patients diagnose `` de novo '' . 2 . Patients prior antihypertensive treatment monotherapy respond treatment , investigator 's opinion , could benefit diuretic treatment monotherapy . 3 . Patients prior antihypertensive treatment monotherapy tolerate current treatment , investigator 's opinion , could benefit diuretic treatment monotherapy . Patients prior treatment must able interrupt present treatment period 3 month . ( Mild moderate hypertension define blood pressure level : Systolic blood pressure 140179 mm Hg diastolic blood pressure 90109 mm Hg ) ( 2003 European Society HypertensionEuropean Society Cardiology guideline management arterial hypertension ) ( 3 ) 3 . Capable understanding nature trial . 4 . Providing informed consent writing . 1 . Pregnant breastfeed woman woman fertile age use safe contraceptive method intend use one trial . Safe contraceptive method oral parenteral contraceptive treatment barrier method : masculine feminine condom , diaphragm and/or IUD . 2 . Severe arterial hypertension ( systolic blood pressure 180 mmHg diastolic blood pressure 110 mmHg ) . 3 . Known suspected secondary arterial hypertension . 4 . History known hypersensitivity compound study sulfonylurea . 5 . History repeat documented hypertensive crisis . 6 . NYHA grade II IV congestive heart failure . 7 . Severe cardiac arrhythmia ( sustain ventricular tachycardia , auricular fibrillation , auricular flutter , bradycardia 45 beat per minute ) . 8 . Unstable angina pectoris . 9 . Acute myocardial infarct last 6 month . 10 . Liver failure define follow analytical parameter : SGPT ( ALT ) SGOT ( AST ) twice upper normal limit . 11 . Chronic kidney failure define follow analytical parameter : Serum creatinine 2.3 mg/dl ( 203 mol/L ) . 12 . Patients insulindependent diabetes patient noninsulin dependent diabetes . 13 . Cerebrovascular accident last 6 month . 14 . Contraindications data obtain selection process physical examination , haematology , biochemistry , urine analysis 12lead ECG , investigator 's opinion . 15 . Simultaneous participation another clinical trial treatment investigational drug within 30 day prior sign inform consent form . 16 . Lactose intolerance . 17 . Concomitant treatment lithium . 18 . Patients require chronic treatment ( treatment &gt; 7 day ) nonsteroidal antiinflammatory drug , include aspirin . 19 . Patients concomitant treatment aminoglycoside antibiotic , etacrynic acid . 20 . Chronic administration medication affect blood pressure . 21 . Patients treatment group 1a , 1b 2 antiarrhythmic drug . 22 . History drug alcohol addiction within 6 month prior start trial . 23 . Any clinical circumstance condition , investigator 's opinion , could affect possibility complete protocol administration Torasemide . 24 . Obesity body mass index ( BMI ) 40 kg/m2 . 25 . Patients respond diuretic treatment monotherapy . 26 . Patients prior antihypertensive treatment monotherapy candidate antihypertensive treatment polytherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Anti-hypertensive effect</keyword>
	<keyword>Diuretic</keyword>
</DOC>